The Company’s neurodegenerative clinical program remains on track, with continued advancement of the Alzheimer’s Phase 2 trial and anticipation of Parkinson’s Phase 1/2a trial initiation.
NKGen Biotech Garante Financiamento Adicional de 5 Milhões de Dólares para Continuar a Avançar os Seus Programas Clínicos
